Pomerantz Law Firm Investigates Potential Securities Fraud Claims Against Capricor Therapeutics, Inc.

Investigation Announcement

The Pomerantz Law Firm has announced their investigation regarding the investors of Capricor Therapeutics, Inc. (NASDAQ: CAPR) as they explore potential claims of securities fraud. Investors who believe they have been adversely affected are encouraged to reach out to Danielle Peyton at Pomerantz LLC for more information about their rights and the possible implications of this investigation.

Background on Capricor Therapeutics

Founded with the vision of creating innovative cell therapies, Capricor Therapeutics focuses on developing treatments for serious medical conditions. One of their significant projects involves deramiocel, an investigational cell therapy designed to treat patients diagnosed with Duchenne muscular dystrophy (DMD) cardiomyopathy. Recent developments regarding this treatment have raised several concerns within the investor community, leading to the ongoing investigation.

FDA Interaction and Stock Decline

A crucial moment in Capricor's timeline occurred on May 5, 2025, when the company released information about its Biologics License Application (BLA) for deramiocel. The U.S. Food and Drug Administration (FDA) indicated a willingness to hold an advisory committee meeting, which should have been positive news. However, in an unexpected turn, the next day, the company's stock price witnessed a dramatic decline, plummeting by $3.00 to end at $7.30. This represented a staggering drop of approximately 29.13%.

Cancellation of Advisory Meeting

The situation worsened on June 20, 2025, when reports from STAT revealed that the newly appointed leader of the FDA's relevant division had decided to cancel the advisory meeting. This decision stemmed from uncertainties surrounding the efficacy and safety of deramiocel. Following this news, Capricor's stock price dropped further—this time by $3.68, bringing it down to $8.26 per share, which translates to a 30.82% dip. These significant price fluctuations sparked investor concerns, prompting the legal investigation led by Pomerantz.

Pomerantz Law Firm's Role

With a legacy spanning over 85 years, Pomerantz LLP has established itself as a leader in corporate litigation, notably in securities class actions. Founded by the renowned Abraham L. Pomerantz, the firm is dedicated to advocating for victims of corporate misconduct, securities fraud, and breaches of fiduciary duty. They have successfully secured substantial damages for class members over the years, reinforcing their commitment to justice within the investor community.

Next Steps for Investors

Investors from Capricor Therapeutics, Inc. who believe they may have been misled or adversely affected by the above events are urged to contact Pomerantz LLP. They can reach Danielle Peyton directly at the firm's office or via email. Joining the class action could offer investors a path to recover their losses if they were impacted by the recent declines related to the company's stock performance.

Conclusion

The current investigation is crucial for ensuring that investor rights are protected and that transparency is maintained within the market. As the situation unfolds, stakeholders will be keeping a close watch on Pomerantz LLP's progress and any forthcoming developments from Capricor Therapeutics. This incident serves as a reminder of the volatility present in the biotechnology sector and its implications for investors.

For further details and updates on this investigation, potential claimants are encouraged to monitor the announcements from the Pomerantz Law Firm. Their extensive experience and commitment to addressing securities fraud could help many investors seek the justice they deserve.